Elutia Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELUT research report →
Companyelutia.com
Elutia Inc. , a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular.
- CEO
- C. Randal Mills
- IPO
- 2020
- Employees
- 51
- HQ
- Silver Spring, MD, US
Price Chart
Valuation
- Market Cap
- $52.17M
- P/E
- 1.02
- P/S
- 3.27
- P/B
- 2.25
- EV/EBITDA
- -1.64
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 54.02%
- Op Margin
- -159.43%
- Net Margin
- 312.09%
- ROE
- -560.64%
- ROIC
- -79.55%
Growth & Income
- Revenue
- $12.29M · -49.57%
- Net Income
- $53.38M · 198.95%
- EPS
- $1.29 · 169.35%
- Op Income
- $-18,412,000
- FCF YoY
- -100.27%
Performance & Tape
- 52W High
- $2.64
- 52W Low
- $0.50
- 50D MA
- $1.08
- 200D MA
- $1.08
- Beta
- 0.76
- Avg Volume
- 133.41K
Get TickerSpark's AI analysis on ELUT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 10, 25 | NEELS GUIDO J | other | 6,250 |
| Dec 10, 25 | NEELS GUIDO J | other | 6,250 |
| Mar 10, 26 | Williams Michelle LeRoux | other | 12,500 |
| Mar 10, 26 | Williams Michelle LeRoux | other | 4,613 |
| Mar 10, 26 | Williams Michelle LeRoux | other | 12,500 |
| Mar 10, 26 | Ferguson Matthew | other | 12,500 |
| Mar 10, 26 | Ferguson Matthew | other | 5,123 |
| Mar 10, 26 | Mills C Randal | other | 27,084 |
| Mar 10, 26 | Mills C Randal | other | 11,100 |
| Mar 10, 26 | Mills C Randal | other | 27,084 |
Our ELUT Coverage
We haven't published any research on ELUT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ELUT Report →